ArticleInfection2021
C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19.
Article in Infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Predictive values of procalcitonin for coinfections in patients with COVID-19: a systematic review and meta-analysis.Virology journal · 2023Pooled it
- Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis.The Lancet. Microbe · 2023Pooled it
- Host-response biomarker panels for distinguishing selected acute respiratory viral-bacterial co-infections from mono-infections.iScience · 2026Review
- Article
- Narrative Review: Research Progress and Future Directions of Presepsin in Neurological Prognostication of Adult Post-Return of Spontaneous Circulation (Post-ROSC) Cardiac Arrest Survivors.Journal of inflammation research · 2026Review
- Empirical antibiotic prescribing in COVID-19 patients: patterns and predictors in a resource-constrained Central Indian setting.Frontiers in antibiotics · 2026Article
- A novel nomogram for the early identification of coinfections in elderly patients with coronavirus disease 2019.Virology journal · 2025Observational
- Vitamin D Serum Levels and the Development of Intensive Care Unit-Acquired Weakness: Insights from a COVID-19 Intensive Care Cohort.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Evaluation of candidemia cases in the intensive care unit of a tertiary training hospital during the period of COVID-19 pandemic.BMC infectious diseases · 2025Article
- Elevated Serum Presepsin Identifies Herpes Simplex Virus-1 Reactivation in COVID-19 Patients.Viruses · 2025Article
- Plasma Lipopolysaccharide-Binding Protein (LBP) Is Induced in Critically Ill Females with Gram-Negative Infections-Preliminary Study.Infectious disease reports · 2025Article
- The Influence of COVID-19 on Antimicrobial Resistance Trends at a Secondary Care Hospital in Slovenia: An Interrupted Time Series Analysis.Antibiotics (Basel, Switzerland) · 2024Article
- To prescribe or not: a two-center retrospective observational study of antibiotics usage and outcomes of COVID-19 in Turkey.Scientific reports · 2024Observational
- Evaluation of cardiac biomarkers among dead and alive COVID-19 patients in Southwest Iran.Journal of family medicine and primary care · 2024Article
- Calprotectin, a Promising Serological Biomarker for the Early Diagnosis of Superinfections with Multidrug-Resistant Bacteria in Patients with COVID-19.International journal of molecular sciences · 2024Article
- The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19.EBioMedicine · 2024Article
- Demystifying COVID-19 mortality causes with interpretable data mining.Scientific reports · 2024Article
- Role of biomarkers in antimicrobial stewardship: physicians' perspectives.The Korean journal of internal medicine · 2024Article
- Development and validation of machine learning-based models for predicting healthcare-associated bacterial/fungal infections among COVID-19 inpatients: a retrospective cohort study.Antimicrobial resistance and infection control · 2024Article
- Antimicrobial Use during the SARS-CoV-2 Pandemic in a Greek Tertiary University Hospital.Microorganisms · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread around the world. Differentiation between pure viral COVID-19 pneumonia and secondary infection can be challenging. In patients with elevated C-reactive protein (CRP) on admission physicians often decide to prescribe antibiotic therapy. However, overuse of anti-infective therapy in the pandemic should be avoided to prevent increasing antimicrobial resistance. Procalcitonin (PCT) and CRP have proven useful in other lower respiratory tract infections and might help to differentiate between pure viral or secondary infection.
methodsWe performed a retrospective study of patients admitted with COVID-19 between 6th March and 30th October 2020. Patient background, clinical course, laboratory findings with focus on PCT and CRP levels and microbiology results were evaluated. Patients with and without secondary bacterial infection in relation to PCT and CRP were compared. Using receiver operating characteristic (ROC) analysis, the best discriminating cut-off value of PCT and CRP with the corresponding sensitivity and specificity was calculated.
resultsOut of 99 inpatients (52 ICU, 47 Non-ICU) with COVID-19, 32 (32%) presented with secondary bacterial infection during hospitalization. Patients with secondary bacterial infection had higher PCT (0.4 versus 0.1 ng/mL; p = 0.016) and CRP (131 versus 73 mg/L; p = 0.001) levels at admission and during the hospital stay (2.9 versus 0.1 ng/mL; p < 0.001 resp. 293 versus 94 mg/L; p < 0.001). The majority of patients on general ward had no secondary bacterial infection (93%). More than half of patients admitted to the ICU developed secondary bacterial infection (56%). ROC analysis of highest PCT resp. CRP and secondary infection yielded AUCs of 0.88 (p < 0.001) resp. 0.86 (p < 0.001) for the entire cohort. With a PCT cut-off value at 0.55 ng/mL, the sensitivity was 91% with a specificity of 81%; a CRP cut-off value at 172 mg/L yielded a sensitivity of 81% with a specificity of 76%.
conclusionPCT and CRP measurement on admission and during the course of the disease in patients with COVID-19 may be helpful in identifying secondary bacterial infections and guiding the use of antibiotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.